| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Zheng, Song Guo Wang, Xuehao Chen, Maogen Gu, Jian Olsen, Nancy Wang, Ping Lan, Qin Li, Qiang Liu, Zhongmin Chen, Guihua Xu, Lili Brand, David Lu, Ling |
| Description |
Author Affiliation: Gu J ( Department of Liver Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China); Lu L ( Department of Liver Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China); Chen M ( Organ Transplant Center, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China); Xu L ( Department of Molecular Biosciences, Stockholm University, SE-10691 Stockholm, Sweden); Lan Q ( Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China); Li Q ( Organ Transplant Center, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China); Liu Z ( Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China); Chen G ( Clinical Immunology Section, Third Affiliated Hospital at Sun Yat-Sen University, Guangzhou 510630, China); Wang P ( Department of Liver Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China); Wang X ( Department of Liver Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China); Brand D ( Research Service, Veterans Affairs Medical Center, Memphis, TN 38104.); Olsen N ( Division of Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033); Zheng SG ( Division of Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033) |
| Abstract |
The use of TGF-ß-induced CD4(+)Foxp3(+) T cells (induced regulatory T cells [iTregs]) is an important prevention and treatment strategy in autoimmune diseases and other disorders. However, the potential use of iTregs as a treatment modality for acute graft-versus-host disease (aGVHD) has not been realized because they may be unstable and less suppressive in this disease. We restudied the ability of iTregs to prevent and treat aGVHD in two mouse models. Our results showed that, as long as an appropriate iTreg-generation protocol is used, these iTregs consistently displayed a potent ability to control aGVHD development and reduce mortality in the aGVHD animal models. iTreg infusion markedly suppressed the engraftment of donor CD8(+) cells and CD4(+) cells, the expression of granzyme A and B, the cytotoxic effect of donor CD8(+) cells, and the production of T cell cytokines in aGVHD. Therefore, we conclude that as long as the correct methods for generating iTregs are used, they can prevent and even treat aGVHD. |
| ISSN |
00221767 |
| e-ISSN |
15506606 |
| DOI |
10.4049/jimmunol.1400207 |
| Journal |
The Journal of Immunology |
| Issue Number |
7 |
| Volume Number |
193 |
| Language |
English |
| Publisher |
The American Association of Immunologists |
| Publisher Date |
2014-10-01 |
| Publisher Place |
United States |
| Access Restriction |
Open |
| Subject Keyword |
Cd8-positive T-lymphocytes Immunology Graft Vs Host Disease T-lymphocytes, Regulatory Transforming Growth Factor Beta Acute Disease Animals Pathology Disease Models, Animal Forkhead Transcription Factors Therapy Granzymes Lymphocyte Transfusion Mice Mice, Inbred Balb C Mice, Inbred Dba Transplantation Research Support, N.i.h., Extramural Research Support, Non-u.s. Gov't Discipline Immunology |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Immunology and Allergy Immunology |
